



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the [Library Thesis Consent Form](#) and [Deposit Licence](#).

Note : Masters Theses

The digital copy of a masters thesis is as submitted for examination and contains no corrections. The print copy, usually available in the University Library, may contain corrections made by hand, which have been requested by the supervisor.

Emerging Concepts In The Pathophysiology Of Acute Pancreatitis

Anubhav Mittal

*A thesis submitted in fulfilment of the requirements for a degree of Doctor of
Philosophy in Surgery, The University of Auckland, 2010.*

Abstract

There is no specific treatment for acute pancreatitis (AP) reflecting an incomplete understanding of the critical pathophysiological factors that determine severity, drive multiple organ dysfunction (MODS) and cause the high mortality. New treatment paradigms are needed, and this thesis explores three paradigms that may offer novel approaches to severity assessment and treatment.

Patients with acute pancreatitis are prone to hypotension and oxidative stress. Cyclic voltammetry (CyV) was adapted to measure serum redox status during both experimental AP and shock. CyV was found to accurately reflect disease severity. Clinical trials are now needed to demonstrate the feasibility and utility of this approach at the bedside for real-time monitoring of the antioxidant capacity of patients and response to resuscitation.

There is preliminary evidence to suggest that MODS might be mediated by toxic factors in the protein fraction of disease conditioned mesenteric lymph (ML). Using the advanced proteomic techniques of isobaric tags (iTRAQ™) for relative protein quantitation together with liquid chromatography–tandem mass spectrometry for the identification of the component proteins, the first comprehensive description of the normal (fasted and fed) rodent ML proteome is provided in this thesis. This was followed by separate studies to define ML proteome in AP and systemic shock. A bioinformatics approach was applied to identify key pathways and significant protein-protein interactions.

The relatively new concept of cytopathic hypoxia has not been investigated in AP, even though mitochondrial dysfunction (MD) plays a key role in the development of MODS. Here, it was shown that significant MD was present, as expected, in the pancreas and lung, but also in the jejunum early in AP. These findings justify the further investigation of mitochondrial specific therapies in AP.

To my wife, Dipti Lath Mittal, for her invaluable support and encouragement.

Acknowledgements

The work presented here would not have been possible without the constant encouragement, guidance and supervision of Prof. J. A. Windsor and Dr. A. Phillips. I am indebted to them for their supervision of my research.

I would also like to thank the following people:

- Prof. G. Cooper for allowing me to use his laboratory facilities at the School of Biological Sciences.
- Dr. P. Kilmartin for allowing me to use his laboratory facilities at the Department of Chemistry and for help in establishing the electrophysiology protocols.
- Prof. B. Delahunt for help with reading the histology slides.
- Mr. M. Middleditch for help with running the Qstar LC-MS/MS used for the proteomic studies.
- Dr. K. Ruggiero for help with biostatistical analysis of the proteomic data.
- Dr. A. Hickey for help with establishing the protocols used for the mitochondrial study.
- Mr. V. Tintinger and Ms. A. Petzer for help in looking after the animal laboratories.
- Dr. B. Loveday for his friendship and support during the PhD.
- Ms. L. Blackwell for help with various administrative issues.

I would like to acknowledge the Royal Australasian College of Surgeons for financial support in the form of a personal scholarship which allowed me to pursue fulltime

research towards this PhD.

Table of Contents

CHAPTER 1. TRADITIONAL CONCEPTS IN THE PATHOPHYSIOLOGY OF ACUTE PANCREATITIS.....	1
1.1. ACUTE PANCREATITIS.....	1
1.2. PATHOPHYSIOLOGY OF ACUTE PANCREATITIS.....	2
1.2.1 <i>Initial trigger</i>	2
1.2.2 <i>Acinar cell events</i>	3
1.2.3 <i>Extra-acinar cell events</i>	9
1.2.4 <i>Multiple organ dysfunction syndrome and death in severe AP</i>	19
1.3. CONCLUSIONS.....	21
CHAPTER 2. EMERGING CONCEPTS IN THE PATHOPHYSIOLOGY OF ACUTE PANCREATITIS.....	22
2.1. ROLE OF THE INTESTINE IN ACUTE PANCREATITIS.....	22
2.1.1 <i>Hypovolaemia and reflex splanchnic vasoconstriction</i>	22
2.1.2 <i>Intestinal ischaemia-reperfusion and generation of reactive oxygen species</i>	24
2.1.3 <i>The 'Gut starter' vs. 'Gut motor'</i>	27
2.2. MESENTERIC LYMPH.....	29
2.2.1 <i>Disease conditioned mesenteric lymph</i>	29
2.2.2 <i>Intestinal ischaemia, mesenteric lymph and acute pancreatitis</i>	29
2.3. MITOCHONDRIAL DYSFUNCTION AND ACUTE PANCREATITIS.....	31
2.4. CONCLUSIONS.....	32
2.4.1 <i>The measurement of oxidative stress in acute pancreatitis</i>	32
2.4.2 <i>Disease conditioned mesenteric lymph</i>	33
2.4.3 <i>Mitochondrial dysfunction</i>	34
CHAPTER 3. METHODS.....	37
3.1. ANIMAL PREPARATION AND HANDLING.....	37
3.2. ANAESTHESIA (NON-RECOVERY).....	38
3.2.1 <i>Isoflurane anaesthesia</i>	38
3.2.2 <i>Ventilation</i>	40
3.2.3 <i>Temperature</i>	42
3.2.4 <i>Intravenous and intra-arterial lines</i>	43
3.2.5 <i>Monitoring of blood pressure</i>	45
3.2.6 <i>Intravenous fluid regimen</i>	47
3.3. ANAESTHESIA (RECOVERY).....	48
3.3.1 <i>Induction and anaesthesia</i>	48
3.3.2 <i>Analgesia</i>	48
3.3.3 <i>Recovery</i>	49
3.4. DISEASE MODELS.....	50
3.4.1 <i>Controlled shock</i>	50
3.4.2 <i>Acute Pancreatitis</i>	51
3.5. SPECIMEN COLLECTION.....	53
3.5.1 <i>Mesenteric lymph</i>	53
3.5.2 <i>Blood</i>	55
3.5.3 <i>Organs for histology</i>	56
3.5.4 <i>Organs for assessment of mitochondrial function</i>	58

3.5.5 Urine	59
3.6. SPECIMEN ANALYSIS.....	60
3.6.1 Blood biochemistry	60
3.6.2 Measure of total antioxidant status	61
3.6.3 Histology.....	63
3.6.4 Proteomic analysis	67
3.6.5 Assessment of mitochondrial function.....	69
CHAPTER 4. THE REDOX STATUS OF ACUTE PANCREATITIS AS MEASURED BY CYCLIC VOLTAMMETRY	74
4.1. INTRODUCTION	74
4.1.1 Total Antioxidant Capacity vs. Antioxidant Status	74
4.1.2 Cyclic Voltammetry.....	75
4.1.3 Aim	76
4.2. METHODS	76
4.2.1 Animals.....	76
4.2.2 Study Design.....	76
4.2.3 Acute Pancreatitis Model	77
4.2.4 Assays and Histology.....	77
4.2.5 Cyclic Voltammetry.....	77
4.2.6 Statistics.....	81
4.3. RESULTS	81
4.3.1 Acute Pancreatitis Model	81
4.3.2 Cyclic Voltammetry and Pancreatitis Severity.....	82
4.3.3 Cyclic voltammetry and low molecular weight anti-oxidants	83
4.3.4 Total Antioxidant Capacity.....	84
4.3.5 Uric Acid and Ascorbic Acid Contribution to CV _{i1}	87
4.4. DISCUSSION.....	89
4.4.1 CV _{i1} and Pancreatitis Severity	89
4.4.2 Cyclic Voltammetry vs. ABST ⁺ based Total Antioxidant Capacity	89
4.4.3 Contribution to the CV _{i1} peak.....	90
4.4.4 Limitations.....	90
4.5. CONCLUSION	91
CHAPTER 5. CYCLIC VOLTAMMETRY CAN MEASURE REDOX STATUS IN SYSTEMIC SHOCK AND RECOVERY FROM ACUTE PANCREATITIS.....	92
5.1. INTRODUCTION	92
5.1.1 Aims	93
5.2. METHODS	93
5.2.1 Animals.....	93
5.2.2 Disease models.....	94
5.2.3 Study Design.....	95
5.2.4 Assays and Histology.....	95
5.2.5 Cyclic Voltammetry.....	96
5.2.6 Statistics.....	97
5.3. RESULTS	98
5.3.1 Controlled Shock Model.....	98
5.3.2 Acute Pancreatitis Model	98

5.3.3 Recovery Acute Pancreatitis Model	100
5.3.4 First cyclic voltammetric peak.....	102
5.3.5 Second cyclic voltammetry peak.....	103
5.3.6 Other Correlations.....	104
5.4. DISCUSSION.....	105
5.4.1 Limitations.....	108
5.5. CONCLUSION	108
CHAPTER 6. THE PROTEOME OF NORMAL RODENT MESENTERIC LYMPH IN FASTED AND FED STATES.....	110
6.1. INTRODUCTION	110
6.1.1 Composition of mesenteric lymph.....	110
6.1.2 Mesenteric lymph and critical illness.....	113
6.1.3 Aims	114
6.2. METHODS	114
6.2.1 Animals.....	114
6.2.2 Study Design.....	114
6.2.3 Collection of Mesenteric Lymph.....	115
6.2.4 Depletion of the abundant proteins.....	115
6.2.5 Proteomics	117
6.2.6 Statistics.....	120
6.3. RESULTS	121
6.3.1 Fed-Fasted Model.....	121
6.3.2 Effect of Depletion	121
6.3.3 Description of the Mesenteric Lymph Proteome	123
6.3.4 Comparing Fasted and Fed Mesenteric Lymph	136
6.4. DISCUSSION.....	138
6.4.1 More Than A Filtrate of Plasma	138
6.4.2 Immunodepletion.....	139
6.4.3 Previous Gel-Based Proteomic Analysis of Mesenteric lymph	139
6.4.4 Mesenteric Lymph Composition	140
6.4.5 Hypothetical Proteins	142
6.4.6 Mesenteric Lymph in Health and Disease	143
6.4.7 Limitations.....	144
6.5. CONCLUSION	145
CHAPTER 7. THE PROTEOME OF MESENTERIC LYMPH DURING ACUTE PANCREATITIS AND IMPLICATIONS FOR TREATMENT	146
7.1. INTRODUCTION	146
7.1.1 Aims	146
7.2. METHODS	147
7.2.1 Animals.....	147
7.2.2 Study Design.....	147
7.2.3 Acute pancreatitis model.....	148
7.2.4 Collection of mesenteric lymph.....	148
7.2.5 Histology and assays	148
7.2.6 Proteomics	149
7.2.7 Statistics.....	152

7.2.8 Bioinformatics.....	153
7.3. RESULTS	154
7.3.1 Validation of the acute pancreatitis model.....	154
7.3.2 Mesenteric lymph proteomics	157
7.4. DISCUSSION.....	160
7.5. CONCLUSION.....	165
CHAPTER 8. CHANGES IN THE MESENTERIC LYMPH PROTEOME INDUCED BY CONTROLLED SHOCK	166
8.1. INTRODUCTION	166
8.1.1 Aims	166
8.2. METHODS.....	167
8.2.1 Animals.....	167
8.2.2 Study Design.....	167
8.2.3 Controlled shock model.....	168
8.2.4 Collection of mesenteric lymph.....	168
8.2.5 Histology and assays	168
8.2.6 Proteomics.....	169
8.2.7 Statistics.....	169
8.2.8 Bioinformatics.....	170
8.3. RESULTS	171
8.3.1 Validation of the controlled shock model.....	171
8.3.2 Mesenteric lymph proteomics	175
8.3.3 Bioinformatics.....	185
8.4. DISCUSSION.....	190
8.4.1 Verification of the CS-model.....	190
8.4.2 Pancreatic enzymes in CS-ML.....	191
8.4.3 Gene Ontology pathway analysis.....	191
8.4.4 Interactome.....	193
8.4.5 Previous gel-based proteomic studies.....	194
8.4.6 Limitations.....	195
8.4.7 Conclusion.....	196
CHAPTER 9. EARLY MITOCHONDRIAL DYSFUNCTION FOUND IN JEJUNUM AND LUNG DURING EARLY EXPERIMENTAL ACUTE PANCREATITIS.....	198
9.1. INTRODUCTION	198
9.1.1 Aims	199
9.2. METHODS.....	200
9.2.1 Animals.....	200
9.2.2 Study Design.....	200
9.2.3 Caerulein induced acute pancreatitis.....	200
9.2.4 Taurocholate induced acute pancreatitis.....	201
9.2.5 Biochemistry and histology.....	201
9.2.6 Assessment of mitochondrial function.....	201
9.2.7 Incubation of lung tissue with caerulein	202
9.2.8 Statistics.....	202
9.3. RESULTS	203
9.3.1 Effect of acute pancreatitis on pancreatic mitochondria	205

9.3.2 Effect of anaesthesia and surgery on mitochondrial function.....	205
9.3.3 Effect of acute pancreatitis on distant organ mitochondrial function.....	206
9.3.4 No direct effect of caerulein on lung mitochondrial function.....	212
9.4. DISCUSSION.....	213
9.4.1 Effect of acute pancreatitis on pancreatic mitochondria.....	213
9.4.2 Effect of acute pancreatitis on lung mitochondrial function.....	214
9.4.3 Effect of anaesthetic and sham surgery on lung mitochondrial function.....	215
9.4.4 Effect of acute pancreatitis on intestinal mitochondrial function.....	215
9.4.5 No effect of acute pancreatitis on hepatic mitochondrial function.....	217
9.4.6 Limitations.....	217
9.4.7 Significance.....	218
9.4.8 Further Research.....	218
9.5. CONCLUSION.....	219
CHAPTER 10. SUMMARY AND CONCLUSIONS.....	220
10.1. THE MEASUREMENT OF OXIDATIVE STRESS IN ACUTE PANCREATITIS.....	221
10.1.1 Background and summary of current work.....	221
10.1.2 Future research.....	222
10.2. DEFINING THE PROTEOME OF MESENTERIC LYMPH.....	223
10.2.1 Background and summary of current work.....	223
10.2.2 Future research.....	224
10.3. EARLY MITOCHONDRIAL DYSFUNCTION DURING ACUTE PANCREATITIS.....	225
10.3.1 Background and summary of current work.....	225
10.3.2 Future research.....	226
10.4. CONCLUSION.....	227
REFERENCES.....	228
SUPPLEMENTARY TABLES.....	250

List of Figures

FIGURE 1-1 SUMMARY OF THE GENERATION AND EFFECTS OF REACTIVE OXYGEN SPECIES (ROS) DURING ACUTE PANCREATITIS. HIGHLIGHTED TEXT WITH BLACK BACKGROUND SHOWS THE INDIRECT MARKERS OF OXIDATIVE STRESS THAT ARE CURRENTLY AVAILABLE IN THE LABORATORY SETTING.	18
FIGURE 2-1 THE IMPORTANT ROLE OF INTESTINAL ISCHAEMIA-REPERFUSION INJURY IN LINKING TOGETHER SEVERE ACUTE PANCREATITIS AND MULTIPLE ORGAN DYSFUNCTION SYNDROME	24
FIGURE 2-2 THE ROLE OF XANTHINE OXIDASE IN INTESTINAL ISCHAEMIA-REPERFUSION INJURY.....	26
FIGURE 2-3 PANCREATIC MICROCIRCULATION IN A SODIUM TAUROCHOLATE (TC) MODEL OF RODENT ACUTE PANCREATITIS (AP) WITH THE ADDITION OF: A - DONOR LYMPH COLLECTED AFTER VARYING DURATIONS OF INTESTINAL ISCHAEMIA-REPERFUSION (IIR); B - INFUSION OF NORMAL LYMPH (N-LYMPH) AND IIR-CONDITIONED MESENTERIC LYMPH (IIR-LYMPH). THERE WAS A DECREASE IN THE VELOCITY OF BLOOD FLOW IN THE PANCREATIC MICROCIRCULATION FOLLOWING THE INDUCTION OF AP, WHICH WAS FURTHER EXACERBATED BY EITHER IIR OR THE PERIPHERAL I.V. INFUSION OF IIR- LYMPH. ADAPTED FROM (11)...	39
FIGURE 2-4 SUMMARY OF THE CURRENT UNDERSTANDING OF THE PATHOPHYSIOLOGY OF ACUTE PANCREATITIS. AREAS INVESTIGATED IN THIS THESIS ARE HIGHLIGHTED IN BLUE.....	36
FIGURE 3-1 RODENT HOUSING IN A STANDARD PLASTIC BOX LINED WITH PINE WOOD SHAVINGS.	38
FIGURE 3-2 FUME HOOD FOR INDUCTION OF ANAESTHESIA.....	39
FIGURE 3-3 ANIMAL LABORATORY SETUP WITH THE LEICA M500 OPERATING MICROSCOPE (LEICA MICROSYSTEMS PTY. LTD., GLADESVILLE, NSW, AUSTRALIA).....	40
FIGURE 3-4 TRACHAEOSTOMY.	41
FIGURE 3-5 PICTURE SHOWING THE ANAESTHETIC SETUP WITH THE ANAESTHETIC MACHINE (GEM 9100, CIG HEALTH, DATEX OHMEGA), PRESSURE CONTROLLED VENTILATOR (KENT SCIENTIFIC CORPORATION, TORRINGTON, CT, USA), SC-300 CAPNOGRAPH (PRYON CORPORATION, MENOMONEE FALLS, WI, USA) AND VETTECH VACUUM SCAVENGER (INDEPENDENT VACUUM SERVICES, AUCKLAND, NZ).	42
FIGURE 3-6 RIGHT FEMORAL ARTERY AND VEIN. THE RIGHT FEMORAL VEIN HAS THE 3/0 SILK LIGATURE AROUND IT.	43
FIGURE 3-7 RIGHT FEMORAL VENOUS AND ARTERIAL LINES.....	44
FIGURE 3-8 THE POWERLAB DATA ACQUISITION SYSTEM (ADINSTRUMENTS, DUNEDIN, NEW ZEALAND).....	45
FIGURE 3-9 REAL-TIME MONITORING AND RECORDING OF THE RODENT TEMPERATURE (CHANNEL 1), MEAN ARTERIAL BLOOD PRESSURE (CHANNEL 2), HEART RATE (CHANNEL 3) AND SYSTOLIC/DIASTOLIC BLOOD PRESSURE TRACE (CHANNEL 4 AT THE BOTTOM) FROM THE POWERLAB SYSTEM USING THE LABCHART 5 SOFTWARE (ADINSTRUMENTS, DUNEDIN, NEW ZEALAND).....	46
FIGURE 3-10 GENIE PRECISION PROGRAMMABLE SYRINGE DRIVER (KENT SCIENTIFIC CORPORATION).	47
FIGURE 3-11 CANNULATION OF THE PANCREATICO-BILIARY DUCT FOR THE RETROGRADE INFUSION OF SODIUM TAUROCHOLATE.	52
FIGURE 3-12 MESENTERIC LYMPH TRUNK.....	53
FIGURE 3-13 COLLECTION OF BLOOD BY CARDIAC PUNCTURE.....	55
FIGURE 3-14 HARVESTING THE PANCREAS FOR HISTOLOGY.	56
FIGURE 3-15 HARVESTING OF THE SMALL INTESTINE FOR HISTOLOGY.....	57
FIGURE 3-16 DISPLAYING THE BLADDER PRIOR TO COLLECTION OF URINE.	59
FIGURE 3-17 TWO OROBOROS OXYGRAPHS SIDE-BY-SIDE	70
FIGURE 3-18 REPRESENTATIVE TRACE GENERATED BY THE OROBOROS® OXYGRAPH 2K. SOLID LINE REPRESENTS MITOCHONDRIAL RESPIRATION (LEFT Y-AXIS) AND THE DOTTED LINE REPRESENTS THE OXYGEN CONCENTRATION (RIGHT Y-AXIS). GM2: STATE 2 RESPIRATION WITH GLUTAMATE AND MALATE. GM3: STATE 3 RESPIRATION WITH ADDITION OF ADENOSINE DIPHOSPHATE (ADP). GMS3: STATE 3 RESPIRATION WITH ADDITION OF SUCCINATE. GMSUC: UNCOUPLED RESPIRATION WITH ADDITION OF CARBONYLCYANIDE-4-(TRIFLUOROMETHOXY)-PHENYLHYDRAZONE (FCCP). GMSUCR: ADDITION OF ROTENONE. CCO: ADDITION OF TETRAMETHYL-P-PHENYLENEDIAMINE (TMPD)/ASCORBATE. CCO	

ADDITION OF CYTOCHROME C. CONCOMITANT OXYGEN CONCENTRATION (NMOL/ML) IS SHOWN ON THE RIGHT Y-AXIS.	72
FIGURE 4-1 THE THREE ELECTRODE SYSTEM. STARTING FROM THE LEFT: AG/AGCL REFERENCE ELECTRODE, 3MM GLASSY-CARBON DISK WORKING ELECTRODE, AND THE PLATINUM COUNTER ELECTRODE.....	78
FIGURE 4-2 EXAMPLE OF A TYPICAL SERUM VOLTGRAM OBTAINED DURING OUR STUDY. CV_{I1} : MAGNITUDE OF THE FIRST MAXIMUM CURRENT PEAK. CV_{I2} : MAXIMUM OF THE SECOND PEAK.	79
FIGURE 4-3 TEMPERATURE CONTROLLED GLASS CYV CELL.....	80
FIGURE 4-4 CYCLIC VOLTAMMETRY IN ACTION.	81
FIGURE 4-5 CV_{I1} (MEAN \pm SEM) * INDICATE $P < 0.008$ FOR MANN-WHITNEY U TESTS WITH BONFERRONI CORRECTION.	82
FIGURE 4-6 SPEARMAN CORRELATION OF CV_{I1} WITH PANCREATIC HISTOLOGICAL SEVERITY SCORE.....	83
FIGURE 4-7 URIC ACID AND ASCORBIC ACID CV_{I1} STANDARD CURVES.	87
FIGURE 4-8 PERCENTAGE CONTRIBUTION OF URIC ACID (UA), ASCORBIC ACID (AA) AND 'OTHER' UNDEFINED ANTIOXIDANTS TO MEASURED CV_{I1} . $^{\dagger} P < 0.008$ FOR THE MANN-WHITNEY U TESTS WITH BONFERRONI CORRECTION. ($^{\S} P = 0.012$; $^{\ddagger} P = 0.024$).....	88
FIGURE 5-1 EXAMPLE OF A TYPICAL SERUM VOLTGRAM OBTAINED DURING THE ACUTE STUDY. CV_{I1} : MAGNITUDE OF THE FIRST MAXIMUM CURRENT PEAK, CV_{I2} : MAXIMUM OF THE SECOND PEAK. CS CONTROLLED SHOCK; AP ACUTE PANCREATITIS.....	96
FIGURE 5-2 CV_{I1} AMPLITUDE COMPARED BETWEEN THE CONTROL AND ACUTE PANCREATITIS (150 MINS DURATION) OR SHOCK GROUP (90 MINS HYPOTENSION WITH 60 MINS RESUSCITATION). DATA IS MEAN \pm SEM; MANN-WHITNEY U TEST.....	102
FIGURE 5-3 CV_{I1} AMPLITUDE CHANGES OVER TIME IN RATS WITH RESOLVING ACUTE PANCREATITIS. DATA IS MEAN \pm SEM; MANN-WHITNEY U TEST. (N= 8-11). AP = ACUTE PANCREATITIS. RAP = RESOLVING ACUTE PANCREATITIS	103
FIGURE 5-4 SERUM CV_{I2} BETWEEN THE CONTROL AND THE ACUTE PANCREATITIS (150 MINS DURATION) OR SHOCK GROUPS (90 MINS HYPOTENSION WITH 60 MINS RESUSCITATION). DATA IS MEAN \pm SEM; MANN-WHITNEY U TEST.	104
FIGURE 6-1 iTRAQ LC-MS/MS WORKFLOW.....	119
FIGURE 6-2 SUMMARY OF PROTEIN IDENTIFICATIONS OBTAINED FROM THE FOUR DIFFERENT ANALYTICAL RUNS (SEE TABLE 6-1 FOR RUN DESCRIPTIONS). NUMBERS ARE THE TOTAL SUM OF MUTUALLY IDENTIFIED PROTEINS FOR THE STATED OVERLAPPING PROTOCOLS. NUMBERS WITHIN PARENTHESES ARE THE NUMBER OF 'HYPOTHETICAL' PROTEINS.	122
FIGURE 6-3 PIE CHART OF THE NON-REDUNDANT PROTEINS BASED ON THEIR FUNCTIONAL GROUPS.....	124
FIGURE 6-4 HISTOGRAM SHOWING WHICH PROTEINS ARE INCREASED IN THE FASTED AND FED STATES USING DIFFERENCES IN THE LOG PEAK AREAS OF EACH PROTEIN. HISTOGRAM IS CENTERED ON A MEAN LOG DIFFERENCE OF 0.19 AND A STANDARD DEVIATION (SD) OF 0.42. PROTEINS WITH COEFFICIENTS OF VARIATION $< 35\%$ AND DIFFERENCES BETWEEN 1 AND 2 SDs, AND EXCEEDING 2 SDs ARE LISTED.	137
FIGURE 7-1 PROTOCOL FOR MATCHED COLLECTION OF MESENTERIC LYMPH FOR THE SHAM CONTROL AND ACUTE PANCREATITIS GROUPS.	148
FIGURE 7-2 PROTEIN CONCENTRATION OF ML BETWEEN THE TWO EXPERIMENTAL GROUPS.....	156
FIGURE 8-1 PROTOCOL FOR MATCHED COLLECTION OF MESENTERIC LYMPH FOR THE SHAM CONTROL AND CONTROLLED SHOCK GROUPS.....	167
FIGURE 8-2 CHANGES IN THE MAP 2 MIN PRE-CONTROLLED SHOCK (2 MIN PRE-CS); DURING THE SHOCK PHASE; AND TWO MINUTES POST RESUSCITATION FROM CS (2 MIN POST-CS). MATCHED MAP FROM SHAM ANIMALS ARE ALSO PRESENTED. BLACK BARS – CONTROLLED SHOCK ANIMALS (N=8). GREY BARS – SHAM ANIMALS (N=8). $P < 0.05$ DERIVED USING MANN-WHITNEY U TEST FOR MATCHED TIME POINTS (SHOCK VS. SHAM).....	172
FIGURE 8-3 INTESTINAL HISTOLOGY SCORE (SHAM CONTROL VS. CONTROL SHOCK GROUPS).....	172
FIGURE 8-4 PROTEIN CONCENTRATION OF ML IN THE TWO EXPERIMENTAL GROUPS	174
FIGURE 8-5 FUNCTIONAL GROUP DISTRIBUTION OF THE 60 PROTEINS WITH SIGNIFICANT DIFFERENCE IN THEIR RELATIVE ABUNDANCE (CONTROLLED SHOCK VS. SHAM).	176

FIGURE 8-6 THE GO DISTRIBUTION FOR PROTEINS LISTED IN TABLE 8-2 THAT ARE INVOLVED IN THE FOLLOWING BIOLOGICAL PROCESSES: IMMUNE RESPONSE (R1), DEFENCE RESPONSE (R2), RESPONSE TO STRESS (R3) AND RESPONSE TO CHEMICAL STIMULUS (R4). THESE CODES (R1-4) CORRELATE WITH PROTEINS LISTED IN TABLE 8-2. EACH BOX CONTAINS: THE NAME OF THE PATHWAY, THE GO CLASSIFICATION AND THE NUMBER OF PROTEINS WITH A SIGNIFICANT INCREASE IN THEIR RELATIVE ABUNDANCE (SHOCK VS. SHAM). ONLY PATHWAYS WITH THREE OR MORE PROTEIN CHANGES ASSOCIATED WITH THEM ARE SHOWN.....186

FIGURE 8-7 THE GO DISTRIBUTION FOR PROTEINS LISTED IN TABLE 8-2 THAT ARE INVOLVED IN THE FOLLOWING BIOLOGICAL PROCESSES: CATABOLIC PROCESS (M1), NUCLEOTIDE METABOLIC PROCESS (M2), CARBOHYDRATE METABOLIC PROCESS (M3), ORGANIC ACID METABOLIC PROCESS (M4) AND MONOSACCHARIDE METABOLIC PROCESS (M5). THESE CODES (M1-5) CORRELATE WITH PROTEINS LISTED IN TABLE 8-2. EACH BOX CONTAINS: THE NAME OF THE PATHWAY, THE GO CLASSIFICATION AND THE NUMBER OF PROTEINS WITH A SIGNIFICANT INCREASE IN THEIR RELATIVE ABUNDANCE (SHOCK VS. SHAM). ONLY PATHWAYS WITH THREE OR MORE PROTEINS ASSOCIATED WITH THEM ARE SHOWN.....187

FIGURE 8-8 A VISUAL NETWORK OF THE KNOWN PROTEIN-PROTEIN INTERACTIONS (INTERACTOME) FOR THE PROTEINS LISTED IN TABLE 2, USING THEIR GENE SYMBOLS. IT CAN BE SEEN THE INTERACTIONS MAINLY CLUSTER AROUND 8 PROTEINS: 14-3-3 ZETA, 14-3-3 EPSILON, CALMODULIN, ACTIN, COFILIN 1, PROFILIN 1, PROLYL 4-HYDROLASE, PEPTIDYLPROLYL ISOMERASE, WITH SMALLER CULSTERS AROUND TRANSGELLIN, CYSTATIN C, FATTY ACID BINDING PROTEIN 4 AND ALDOASE A.....189

FIGURE 9-1 A SUMMARY OF THE EFFECTS OF CAERULEIN PANCREATITIS, SHAM SURGERY AND TAUROCHOLATE PANCREATITIS ON THE VARIOUS RESPIRATORY CHAIN COMPLEXES. FOR DEFINITIONS OF GM2 THROUGH TO CCOC SEE LEGEND FOR FIGURE1. '-' REPRESENTS INHIBITION OF THE COMPLEX. LETTERS 'A', 'B' AND 'C' REPRESENT SIGNIFICANT INHIBITION OF THE COMPLEX WHEREBY A: CAERULEIN PANCREATITIS VS. SALINE CONTROL; B: SHAM SURGERY VS. SALINE CONTROL; C: TAUROCHOLATE PANCREATITIS VS. SHAM SURGERY.211

List of Tables

TABLE 1-1 INFLAMMATORY MEDIATORS IMPORTANT IN THE PATHOPHYSIOLOGY OF ACUTE PANCREATITIS	12
TABLE 1-2 NOVEL MEDIATORS OF PANCREATIC MICROCIRCULATION DURING ACUTE PANCREATITIS	15
TABLE 1-3 SEQUENCE OF ORGAN FAILURE DURING CRITICAL ILLNESS	20
TABLE 3-1 SIGNS OF ANIMAL DISTRESS	49
TABLE 3-2 HISTOLOGICAL SCORING SYSTEM FOR SEVERITY OF ACUTE PANCREATITIS	63
TABLE 3-3 HISTOLOGICAL SCORING SYSTEM FOR INTESTINAL INJURY	66
TABLE 4-1 DIAGNOSTIC, HISTOLOGICAL, PHYSIOLOGICAL AND ANTIOXIDANT MARKERS OF SEVERITY IN THE DIFFERENT EXPERIMENTAL GROUPS.....	85
TABLE 4-2 CORRELATION OF THE HISTOLOGICAL SCORE, FIRST CYCLIC VOLTAMETRIC PEAK MAXIMA (CV_{I1}) AND TOTAL ANTIOXIDANT CAPACITY (TAC) WITH RECOGNISED DIAGNOSTIC AND NON-HISTOLOGICAL MARKERS OF ACUTE PANCREATITIS SEVERITY	86
TABLE 4-3 CORRELATION OF FIRST CYCLIC VOLTAMETRIC PEAK MAXIMA (CV_{I1}) WITH KNOWN LOW MOLECULAR WEIGHT ANTIOXIDANTS (LMWA).....	87
TABLE 5-1 HISTOLOGICAL AND SERUM BIOCHEMICAL PARAMETERS IN THE THREE EXPERIMENTAL GROUPS.....	99
TABLE 5-2 HISTOLOGICAL AND SERUM BIOCHEMICAL PARAMETERS IN THE RESOLVING ACUTE PANCREATITIS MODEL	101
TABLE 6-1 DEPLETION AND LC-MS/MS PROTOCOLS.....	116
TABLE 6-2 NON-REDUNDANT LIST OF IDENTIFIED PROTEINS (N = 124).....	125
TABLE 6-3 NON-REDUNDANT LIST OF HYPOTHETICAL PROTEIN IDENTIFICATIONS (N = 26).....	133
TABLE 7-1 HISTOLOGICAL AND SERUM BIOCHEMICAL PARAMETERS IN THE TWO EXPERIMENTAL GROUPS.....	155
TABLE 7-2 LIST OF 8 PROTEINS THAT HAD AN ADJUSTED P VALUE < 0.05 IN THEIR RELATIVE ABUNDANCE BETWEEN THE PANCREATITIS AND SHAM EXPERIMENTAL GROUPS.....	159
TABLE 8-1 HISTOLOGICAL AND BIOCHEMICAL PARAMETERS IN THE TWO EXPERIMENTAL GROUPS.....	173
TABLE 8-2 LIST OF 60 PROTEINS THAT HAD AN ADJUSTED P VALUE < 0.10 IN THEIR RELATIVE ABUNDANCE BETWEEN THE SHAM AND SHOCK EXPERIMENTAL GROUPS.....	177
TABLE 9-1 DIAGNOSTIC, HISTOLOGICAL, AND PHYSIOLOGICAL MARKERS OF SEVERITY IN THE DIFFERENT EXPERIMENTAL GROUPS.....	204
TABLE 9-2 EFFECT OF SURGERY, CAERULEIN INDUCED MILD PANCREATITIS AND TAUROCHOLATE INDUCED SEVERE PANCREATITIS ON MITOCHONDRIAL FUNCTION.....	207
TABLE 9-3 PULMONARY MITOCHONDRIAL RESPIRATION WITH AND WITHOUT INCUBATION WITH CAERULEIN.....	212